{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:05:06Z","timestamp":1793927106846,"version":"4.8.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic low-grade inflammation plays a central role in cardiometabolic disease, yet the associations between lipid metabolism and inflammatory biomarkers in generally healthy individuals remain incompletely understood. This study aimed to investigate the relationship between blood lipids, high-sensitivity C-reactive protein (hsCRP), and a broad panel of inflammatory cytokines in a healthy adult population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 165 healthy participants aged 18\u201344 years were recruited at the Falun County Hospital, Sweden. Blood samples were analyzed for a full lipid profile, blood counts, cytokines, and hsCRP. Plasma inflammatory protein levels were quantified using the Olink Proseek Multiplex Inflammation panel, including 92 cytokines. Statistical analysis included Spearman rank correlations and multiple testing correction using the Benjamini\u2013Hochberg false discovery rate (FDR\u2009&lt;\u20090.10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>hsCRP showed significant correlations with several lipid parameters, particularly remnants, triglycerides, apolipoprotein B (ApoB), and non-HDL cholesterol, as well as with BMI and specific leukocyte counts. Additionally, hsCRP was significantly associated with multiple cytokines, including IL-6, TNF, IL-10, and CXCL10, highlighting a complex pro- and anti-inflammatory milieu.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates correlations between hsCRP, lipid-related biomarkers, and inflammatory cytokines in healthy adults, underscoring the interplay between lipid metabolism and subclinical inflammation. The significant correlations between hsCRP and remnants, ApoB, and cytokines such as IL-6 support the role of these factors as early indicators of cardiometabolic risk, even in the absence of overt disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-026-02939-w","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:35:18Z","timestamp":1775698518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Significant correlations between blood lipids, cytokines, and C-reactive protein in healthy humans"],"prefix":"10.1186","volume":"25","author":[{"given":"Anders","family":"Larsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars B","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3178-4210","authenticated-orcid":false,"given":"Mats","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"2939_CR1","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3389\/fimmu.2018.00430","volume":"9","author":"L Badimon","year":"2018","unstructured":"Badimon L, Pe\u00f1a E, Arderiu G, Padr\u00f3 T, Slevin M, Vilahur G, Chiva-Blanch G. C-Reactive Protein in Atherothrombosis and Angiogenesis. Front Immunol. 2018;9:430. https:\/\/doi.org\/10.3389\/fimmu.2018.00430.","journal-title":"Front Immunol"},{"key":"2939_CR2","doi-asserted-by":"publisher","first-page":"e2404542121","DOI":"10.1073\/pnas.2404542121","volume":"121","author":"DP Noone","year":"2024","unstructured":"Noone DP, Isendoorn MME, Hamers S, Keizer ME, Wulffel\u00e9 J, van der Velden TT, Dijkstra DJ, Trouw LA, Filippov DV, Sharp TH. Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein. Proc Natl Acad Sci U S A. 2024;121:e2404542121. https:\/\/doi.org\/10.1073\/pnas.2404542121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2939_CR3","doi-asserted-by":"publisher","first-page":"1425168","DOI":"10.3389\/fimmu.2024.1425168","volume":"15","author":"HH Zhou","year":"2024","unstructured":"Zhou HH, Tang YL, Xu TH, Cheng B. C-reactive protein: structure, function, regulation, and role in clinical diseases. Front Immunol. 2024;15:1425168. https:\/\/doi.org\/10.3389\/fimmu.2024.1425168.","journal-title":"Front Immunol"},{"key":"2939_CR4","doi-asserted-by":"publisher","first-page":"ofv098","DOI":"10.1093\/ofid\/ofv098","volume":"2","author":"A Markanday","year":"2015","unstructured":"Markanday A. Acute Phase Reactants in Infections: Evidence-Based Review and a Guide for Clinicians. Open Forum Infect Dis. 2015;2:ofv098. https:\/\/doi.org\/10.1093\/ofid\/ofv098.","journal-title":"Open Forum Infect Dis"},{"key":"2939_CR5","doi-asserted-by":"publisher","unstructured":"Verma S, Yeh ET. C-reactive protein and atherothrombosis\u2013beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1253-1256; discussion R1257-1258. https:\/\/doi.org\/10.1152\/ajpregu.00170.2003.\u00a0","DOI":"10.1152\/ajpregu.00170.2003"},{"key":"2939_CR6","doi-asserted-by":"publisher","first-page":"48487","DOI":"10.1074\/jbc.R400025200","volume":"279","author":"S Black","year":"2004","unstructured":"Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004;279:48487\u201390. https:\/\/doi.org\/10.1074\/jbc.R400025200.","journal-title":"J Biol Chem"},{"key":"2939_CR7","doi-asserted-by":"publisher","first-page":"e166117","DOI":"10.1016\/j.amjmed.2005.06.057","volume":"119","author":"I Kushner","year":"2006","unstructured":"Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006;119:e166117\u2013128. https:\/\/doi.org\/10.1016\/j.amjmed.2005.06.057.","journal-title":"Am J Med"},{"key":"2939_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","volume":"120","author":"F Gomez-Delgado","year":"2024","unstructured":"Gomez-Delgado F, Raya-Cruz M, Katsiki N, Delgado-Lista J, Perez-Martinez P. Residual cardiovascular risk: When should we treat it? Eur J Intern Med. 2024;120:17\u201324. https:\/\/doi.org\/10.1016\/j.ejim.2023.10.013.","journal-title":"Eur J Intern Med"},{"key":"2939_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5005\/japi-11001-0009","volume":"70","author":"T Jaishankar","year":"2022","unstructured":"Jaishankar T, Shivasekar M, Vinodhini VM. Assessment of Remnant Lipoprotein Cholesterol and Oxidized Low density Lipoprotein Associated with Low-grade Inflammation in Coronary Heart Disease Subjects of Young South Indian Population. J Assoc Physicians India. 2022;70:11\u20132. https:\/\/doi.org\/10.5005\/japi-11001-0009.","journal-title":"J Assoc Physicians India"},{"key":"2939_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(12)61190-8.","journal-title":"Lancet"},{"key":"2939_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"key":"2939_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf937","author":"B Kurt","year":"2025","unstructured":"Kurt B, Reugels M, Schneider KM, Spiesshoefer J, Milzi A, Gombert A, Fordyce CB, Wenzl FA, Pagidipati NJ, Rocha V, et al. C-reactive protein and cardiovascular risk in the general population. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf937.","journal-title":"Eur Heart J"},{"key":"2939_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/20494637231222327","volume":"18","author":"LB Eriksson","year":"2024","unstructured":"Eriksson LB, Gordh T, Karlsten R, LoMartire R, Thor A, Tegelberg \u00c5. Intravenous S-ketamine\u2019s analgesic efficacy in third molar surgery. A randomized placebo-controlled double-blind clinical trial. Br J Pain. 2024;18:197\u2013208. https:\/\/doi.org\/10.1177\/20494637231222327.","journal-title":"Br J Pain"},{"key":"2939_CR14","doi-asserted-by":"publisher","unstructured":"Eriksson LB, Gordh T, Karlsten R, Thor A, Tegelberg \u00c5. Patient safety of adjunct pre-operative intravenous S-ketamine for pain relief in third molar surgery - a randomised, placebo-controlled, double-blind trial. Br J Pain. 2024;20494637241262509. https:\/\/doi.org\/10.1177\/20494637241262509.","DOI":"10.1177\/20494637241262509"},{"key":"2939_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499\u2013502.","journal-title":"Clin Chem"},{"key":"2939_CR16","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bj\u00f6rkesten J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9:e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192.","journal-title":"PLoS ONE"},{"key":"2939_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12014-023-09393-1","volume":"20","author":"E Skau","year":"2023","unstructured":"Skau E, Wagner P, Leppert J, \u00c4rnl\u00f6v J, Hedberg P. Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable? Clin Proteom. 2023;20:5. https:\/\/doi.org\/10.1186\/s12014-023-09393-1.","journal-title":"Clin Proteom"},{"key":"2939_CR18","unstructured":"STRING. functional protein association networks. Available online: https:\/\/string-db.org. Accessed on 01 Feb 2025."},{"key":"2939_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"2018","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc: Ser B (Methodol). 2018;57:289\u2013300. https:\/\/doi.org\/10.1111\/j.2517-6161.1995.tb02031.x.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"2939_CR20","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ane.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation Coefficients: Appropriate Use and Interpretation. Anesth Analg. 2018;126:1763\u20138. https:\/\/doi.org\/10.1213\/ane.0000000000002864.","journal-title":"Anesth Analg"},{"key":"2939_CR21","unstructured":"WMA Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects. Available online:. Available online: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects. Accessed on 23 Mar 2022."},{"key":"2939_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/circulationaha.123.066213","volume":"149","author":"PM Ridker","year":"2024","unstructured":"Ridker PM, Lei L, Louie MJ, Haddad T, Nicholls SJ, Lincoff AM, Libby P, Nissen SE. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance. Circulation. 2024;149:28\u201335. https:\/\/doi.org\/10.1161\/circulationaha.123.066213.","journal-title":"Circulation"},{"key":"2939_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1161\/jaha.112.000497","volume":"1","author":"PM Ridker","year":"2012","unstructured":"Ridker PM. Hyperlipidemia as an instigator of inflammation: inaugurating new approaches to vascular prevention. J Am Heart Assoc. 2012;1:3\u20135. https:\/\/doi.org\/10.1161\/jaha.112.000497.","journal-title":"J Am Heart Assoc"},{"key":"2939_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.metabol.2012.08.008","volume":"62","author":"N Thongtang","year":"2013","unstructured":"Thongtang N, Diffenderfer MR, Ooi EM, Asztalos BF, Dolnikowski GG, Lamon-Fava S, Schaefer EJ. Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism. Metabolism. 2013;62:369\u201375. https:\/\/doi.org\/10.1016\/j.metabol.2012.08.008.","journal-title":"Metabolism"},{"key":"2939_CR25","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1073\/pnas.94.6.2575","volume":"94","author":"D Xia","year":"1997","unstructured":"Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci U S A. 1997;94:2575\u201380. https:\/\/doi.org\/10.1073\/pnas.94.6.2575.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2939_CR26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1084\/jem.192.9.1353","volume":"192","author":"D Gershov","year":"2000","unstructured":"Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med. 2000;192:1353\u201364. https:\/\/doi.org\/10.1084\/jem.192.9.1353.","journal-title":"J Exp Med"},{"key":"2939_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00365513.2018.1550809","volume":"79","author":"P Ridefelt","year":"2019","unstructured":"Ridefelt P, Hagstr\u00f6m E, Svensson MK, \u00c5kerfeldt T, Larsson A. Age- and sex-specific reference values for non-HDL cholesterol and remnant cholesterol derived from the Nordic Reference Interval Project (NORIP). Scand J Clin Lab Invest. 2019;79:39\u201342. https:\/\/doi.org\/10.1080\/00365513.2018.1550809.","journal-title":"Scand J Clin Lab Invest"},{"key":"2939_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/03009734.2018.1465496","volume":"123","author":"A Larsson","year":"2018","unstructured":"Larsson A, Hagstr\u00f6m E, Nilsson L, Svensson MK. Treatment target re-classification of subjects comparing estimation of low-density lipoprotein cholesterol by the Friedewald equation and direct measurement of LDL-cholesterol. Ups J Med Sci. 2018;123:94\u20139. https:\/\/doi.org\/10.1080\/03009734.2018.1465496.","journal-title":"Ups J Med Sci"},{"key":"2939_CR29","first-page":"303","volume":"47","author":"LJ Rather","year":"1971","unstructured":"Rather LJ. Disturbance of function (functio laesa): the legendary fifth cardinal sign of inflammation, added by Galen to the four cardinal signs of Celsus. Bull N Y Acad Med. 1971;47:303\u201322.","journal-title":"Bull N Y Acad Med"},{"key":"2939_CR30","doi-asserted-by":"publisher","unstructured":"Eriksson MB, Marks-Hultstr\u00f6m M, \u00c5berg M, Lipcsey M, Frithiof R, Larsson AO. Mapping Interactions Between Cytokines, Chemokines, Growth Factors, and Conventional Biomarkers in COVID-19 ICU-Patients. Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms262311419.","DOI":"10.3390\/ijms262311419"},{"key":"2939_CR31","doi-asserted-by":"publisher","first-page":"922422","DOI":"10.3389\/fcimb.2022.922422","volume":"12","author":"MAF Queiroz","year":"2022","unstructured":"Queiroz MAF, Neves P, Lima SS, Lopes JDC, Torres M, Vallinoto I, Bichara CDA, Dos Santos EF, de Brito M, da Silva ALS, et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front Cell Infect Microbiol. 2022;12:922422. https:\/\/doi.org\/10.3389\/fcimb.2022.922422.","journal-title":"Front Cell Infect Microbiol"},{"key":"2939_CR32","doi-asserted-by":"publisher","first-page":"152185","DOI":"10.1016\/j.imbio.2022.152185","volume":"227","author":"AD Dhanda","year":"2022","unstructured":"Dhanda AD, Felmlee D, Boeira P, Moodley P, Tan H, Scalioni LP, Lilly K, Sheridan DA, Cramp ME. Patients with moderate to severe COVID-19 have an impaired cytokine response with an exhausted and senescent immune phenotype. Immunobiology. 2022;227:152185. https:\/\/doi.org\/10.1016\/j.imbio.2022.152185.","journal-title":"Immunobiology"},{"key":"2939_CR33","doi-asserted-by":"publisher","first-page":"1213246","DOI":"10.3389\/fimmu.2023.1213246","volume":"14","author":"TG Paranga","year":"2023","unstructured":"Paranga TG, Pavel-Tanasa M, Constantinescu D, Plesca CE, Petrovici C, Miftode IL, Moscalu M, Cianga P, Miftode EG. Comparison of C-reactive protein with distinct hyperinflammatory biomarkers in association with COVID-19 severity, mortality and SARS-CoV-2 variants. Front Immunol. 2023;14:1213246. https:\/\/doi.org\/10.3389\/fimmu.2023.1213246.","journal-title":"Front Immunol"},{"key":"2939_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/s0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626\u201335. https:\/\/doi.org\/10.1016\/s0140-6736(14)61177-6.","journal-title":"Lancet"},{"key":"2939_CR35","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/circulationaha.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128:1298\u2013309. https:\/\/doi.org\/10.1161\/circulationaha.113.003008.","journal-title":"Circulation"},{"key":"2939_CR36","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12986-025-00982-5","volume":"22","author":"M Han","year":"2025","unstructured":"Han M, Zhou J, Wan Z, Chen M, Yan M, Feng W, Wang G, Zhang J, Zhang L, Yan L, et al. Remnant cholesterol, high-sensitivity C-reactive protein, and risk of incident coronary heart disease among patients with chronic kidney disease based on UK biobank. Nutr Metab (Lond). 2025;22:83. https:\/\/doi.org\/10.1186\/s12986-025-00982-5.","journal-title":"Nutr Metab (Lond)"},{"key":"2939_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ijcard.2004.03.071","volume":"101","author":"K Ikewaki","year":"2005","unstructured":"Ikewaki K, Noma K, Tohyama J, Kido T, Mochizuki S. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia\u2013a nuclear magnetic resonance study. Int J Cardiol. 2005;101:441\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2004.03.071.","journal-title":"Int J Cardiol"},{"key":"2939_CR38","first-page":"539","volume":"33","author":"Y Asanuma","year":"2006","unstructured":"Asanuma Y, Chung CP, Oeser A, Shintani A, Stanley E, Raggi P, Stein CM. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol. 2006;33:539\u201345.","journal-title":"J Rheumatol"},{"key":"2939_CR39","doi-asserted-by":"publisher","unstructured":"Alcover S, Ramos-Regalado L, Gir\u00f3n G, Mu\u00f1oz-Garc\u00eda N, Vilahur G. HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome. Antioxid (Basel). 2025;14. https:\/\/doi.org\/10.3390\/antiox14040434.","DOI":"10.3390\/antiox14040434"},{"key":"2939_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2025.05.006","author":"R Kazibwe","year":"2025","unstructured":"Kazibwe R, Jehopio J, Schaich CL, Rikhi R, Mirzai S, Chevli PA, Namutebi JH, Chebrolu S, O\u2019Connor S, Yeboah J, et al. Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension. Prog Cardiovasc Dis. 2025. https:\/\/doi.org\/10.1016\/j.pcad.2025.05.006.","journal-title":"Prog Cardiovasc Dis"},{"key":"2939_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11886-020-01323-z","volume":"22","author":"MR Langlois","year":"2020","unstructured":"Langlois MR, Sniderman AD. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease? Curr Cardiol Rep. 2020;22:67. https:\/\/doi.org\/10.1007\/s11886-020-01323-z.","journal-title":"Curr Cardiol Rep"},{"key":"2939_CR42","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamacardio.2024.1310","volume":"9","author":"A Sayed","year":"2024","unstructured":"Sayed A, Peterson ED, Virani SS, Sniderman AD, Navar AM. Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels. JAMA Cardiol. 2024;9:741\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2024.1310.","journal-title":"JAMA Cardiol"},{"key":"2939_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","volume":"5","author":"JD Otvos","year":"2011","unstructured":"Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC. Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5:105\u201313. https:\/\/doi.org\/10.1016\/j.jacl.2011.02.001.","journal-title":"J Clin Lipidol"},{"key":"2939_CR44","first-page":"569","volume":"54","author":"T Hayashi","year":"2006","unstructured":"Hayashi T, Hirano T, Shiobara T, Suguro T, Adachi M. [Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol]. Rinsho Byori. 2006;54:569\u201375.","journal-title":"Rinsho Byori"},{"key":"2939_CR45","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/nejm200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836\u201343. https:\/\/doi.org\/10.1056\/nejm200003233421202.","journal-title":"N Engl J Med"},{"key":"2939_CR46","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jacc.2024.07.034","volume":"84","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Gummesson A, Taskinen MR, Burgess S, Packard CJ, Bor\u00e9n J. Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL Cholesterol. J Am Coll Cardiol. 2024;84:1328\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2024.07.034.","journal-title":"J Am Coll Cardiol"},{"key":"2939_CR47","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pcad.2013.10.016","volume":"56","author":"M Bastien","year":"2014","unstructured":"Bastien M, Poirier P, Lemieux I, Despr\u00e9s JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56:369\u201381. https:\/\/doi.org\/10.1016\/j.pcad.2013.10.016.","journal-title":"Prog Cardiovasc Dis"},{"key":"2939_CR48","doi-asserted-by":"publisher","unstructured":"Eriksson MB, Eriksson LB, Larsson AO. Significant Interplay Between Lipids, Cytokines, Chemokines, Growth Factors, and Blood Cells in an Outpatient Cohort. Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms26167746.","DOI":"10.3390\/ijms26167746"},{"key":"2939_CR49","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/circresaha.116.309692","volume":"120","author":"Y D\u00f6ring","year":"2017","unstructured":"D\u00f6ring Y, Soehnlein O, Weber C. Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis. Circ Res. 2017;120:736\u201343. https:\/\/doi.org\/10.1161\/circresaha.116.309692.","journal-title":"Circ Res"},{"key":"2939_CR50","doi-asserted-by":"publisher","unstructured":"Mandel J, Casari M, Stepanyan M, Martyanov A, Deppermann C. Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms23073868.","DOI":"10.3390\/ijms23073868"},{"key":"2939_CR51","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1160\/th11-08-0592","volume":"106","author":"D Lievens","year":"2011","unstructured":"Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost. 2011;106:827\u201338. https:\/\/doi.org\/10.1160\/th11-08-0592.","journal-title":"Thromb Haemost"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02939-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02939-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:11:54Z","timestamp":1776078714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02939-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2939"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02939-w","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}